|
The
company's shares fell 8.6 percent to $352 in trading before the
bell on Friday.
Sales of Biogen's flagship oral multiple sclerosis (MS) drug,
Tecfidera, came in below expectations for the second quarter in
a row, hurt by higher discounting, saturation in the U.S. market
and reports of serious brain infections linked to the drug.
Tecfidera's sales were $833 million in the second quarter ended
June 30, well below Wall Street's estimate of about $933
million, according to Evercore ISI.
Sales of Biogen's injectable MS drug Tysabri came in at $463
million, also falling short of estimates of about $505 million.
Biogen's interferon-based MS drugs Avonex and its new
longer-lasting Plegridy raked in sales of $690 million, far
below expectations of about $767 million.
Overall, the U.S. biotechnology company's sales rose less than
expected. Revenue of $2.59 billion missed analysts' average
estimate of $2.71 billion, according to Thomson Reuters I/B/E/S.
Net profit attributable to Biogen rose 30 percent to $927.3
million, or $3.93 per share. Excluding items, it earned $4.22
per share.
The Cambridge, Massachusetts-based company slashed its full-year
sales growth forecast to 6-8 percent from 14-16 percent. It also
chopped its adjusted profit forecast to $15.50-$15.95 per share
from $16.60-$17 per share.
(Reporting by Natalie Grover in Bengaluru; Editing by Savio
D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
